EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Developments on BACE 1 Inhibitors as Anti‐Alzheimer Agents: A Perspective on Medicinal Chemistry‐Based Advances

Nemat Ali iD, Fahad T Alotaibi, M Arockia Babu, Thakur Gurjeet Singh, Yogita Tyagi, Abdullah N Alotaibi, Nisha Bansal iD, Sarthak Puri iD

Archiv der Pharmazie · 2026-03 · 359 (3)

DOI: 10.1002/ardp.70220 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Archiv der Pharmazie, online erschienen am 16.03.2026. Verfasst von Nemat Ali und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Amyloid Precursor Protein Secretases, Alzheimer Disease, Aspartic Acid Endopeptidases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 177 Literaturangaben. Gefördert von: Deanship of Scientific Research at Imam Mohammad Ibn Saud Islamic University (IMSIU).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is a progressive and complicated neurodegenerative disorder that mostly affects the elderly and is characterized by memory loss, cognitive dysfunction, accumulation of amyloid beta (Aβ) plaques, neurofibrillary tangles, and cholinergic deficits. Current therapies used for AD, such as acetylcholinesterase inhibitors and NMDA receptor antagonist memantine, can only provide temporary or symptomatic relief, but they do not stop or reverse the progression of the disease. Numerous pathogenic hypotheses have been proposed to explain this mechanism; however, the amyloid cascade hypothesis remains the most widely accepted theory, as it suggests that β‐site amyloid precursor protein‐cleaving enzyme 1 (BACE1) plays a critical role in the generation of Aβ peptides. Therefore, BACE1 may be a key therapeutic target. This review primarily focuses on the key role of BACE1 in AD pathogenesis and describes the development of its inhibitors over three generations, explaining their structure, design, and pharmacological properties. While the first generation lacked brain penetration, the second‐generation improved potency but encountered clinical trial failures due to adverse effects. The third generation of these drugs was designed to achieve a balance between efficacy, selectivity, and safety. Additionally, we review the promising molecules currently under clinical investigation, highlighting both their therapeutic potential and the challenges that remain in developing effective disease‐modifying therapies for AD treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Precursor Protein SecretasesAlzheimer DiseaseAspartic Acid EndopeptidasesHumansAnimalsDrug DevelopmentStructure-Activity RelationshipAmyloid beta-PeptidesDrug DesignMolecular StructureChemistry, Pharmaceutical

Stichwörter der Autor:innen

Alzheimer's diseaseBACE1 inhibitorsamyloid βdrug discoveryβ‐amyloid

Substanzen

Amyloid Precursor Protein SecretasesAspartic Acid EndopeptidasesBACE1 protein, humanAmyloid beta-Peptides

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
  • Department of Anatomy and Physiology, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
  • Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India.
  • Centre of Research Impact and Outcome, Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India.
  • Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Premanagar, Dehradun, Uttarakhand, India.
  • Department of Chemistry, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.

ORCID-Profile: Nemat Ali, Nisha Bansal, Sarthak Puri

Förderung

  • Deanship of Scientific Research at Imam Mohammad Ibn Saud Islamic University (IMSIU)

Zitieren

APA

Ali, N., Alotaibi, F. T., Babu, M. A., Singh, T. G., Tyagi, Y., Alotaibi, A. N., Bansal, N., & Puri, S. (2026). Developments on BACE 1 Inhibitors as Anti‐Alzheimer Agents: A Perspective on Medicinal Chemistry‐Based Advances. Archiv der Pharmazie, 359(3). https://doi.org/10.1002/ardp.70220

Vancouver

Ali N, Alotaibi FT, Babu MA, Singh TG, Tyagi Y, Alotaibi AN, et al. Developments on BACE 1 Inhibitors as Anti‐Alzheimer Agents: A Perspective on Medicinal Chemistry‐Based Advances. Archiv der Pharmazie. 2026;359(3). doi:10.1002/ardp.70220

BibTeX
@article{Ali2026,
  author = {Ali, Nemat and Alotaibi, Fahad T and Babu, M Arockia and Singh, Thakur Gurjeet and Tyagi, Yogita and Alotaibi, Abdullah N and Bansal, Nisha and Puri, Sarthak},
  title = {Developments on BACE 1 Inhibitors as Anti‐Alzheimer Agents: A Perspective on Medicinal Chemistry‐Based Advances},
  journal = {Archiv der Pharmazie},
  year = {2026},
  volume = {359},
  number = {3},
  doi = {10.1002/ardp.70220}
}
Kostenlos starten →